Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company developing innovative opioid pain products designed to resist misuse, abuse, and overdose. Its primary platforms include TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistant) prodrug technologies. Lead candidates include PF614, a TAAP oxycodone prodrug, and PF614-MPAR, a combination product with nafamostat. PF614-MPAR received FDA Breakthrough Therapy designation in January 2024. The company is headquartered in La Jolla, California.
expected 2027-02-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001493152-26-013633 | EDGAR | 84K words |
| 2025-03-10 | 2024-12-31 | 0001493152-25-009703 | EDGAR | 83K words |
| 2024-03-15 | 2023-12-31 | 0001493152-24-009993 | EDGAR | 91K words |
| 2023-03-30 | 2022-12-31 | 0001493152-23-009844 | EDGAR | 88K words |
| 2022-03-31 | 2021-12-31 | 0001493152-22-008438 | EDGAR | 88K words |
| 2021-03-15 | 2020-12-31 | 0001213900-21-015361 | EDGAR | 65K words |
| 2020-03-10 | 2019-12-31 | 0001213900-20-005867 | EDGAR | 65K words |
| 2019-03-11 | 2018-12-31 | 0001615774-19-003912 | EDGAR | 63K words |
| 2018-03-09 | 2017-12-31 | 0001615774-18-001769 | EDGAR | 62K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-12 | 2026-09-30 | 0001493152-26-051422 | EDGAR | 27K words |
| 2026-08-13 | 2026-06-30 | 0001493152-26-037817 | EDGAR | 25K words |
| 2025-11-14 | 2025-09-30 | 0001493152-25-023498 | EDGAR | 25K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023512 | EDGAR | 24K words |
| 2025-05-13 | 2025-03-31 | 0001641172-25-009955 | EDGAR | 22K words |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044768 | EDGAR | 23K words |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032263 | EDGAR | 23K words |
| 2024-05-13 | 2024-03-31 | 0001493152-24-018718 | EDGAR | 22K words |
| 2023-11-09 | 2023-09-30 | 0001493152-23-040091 | EDGAR | 30K words |
| 2023-08-11 | 2023-06-30 | 0001493152-23-027659 | EDGAR | 29K words |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017430 | EDGAR | 27K words |
| 2022-11-14 | 2022-09-30 | 0001493152-22-032094 | EDGAR | 32K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-12 | 0001493152-26-051414 | EDGAR | 3K words |
| 2026-11-04 | 0001493152-26-049906 | EDGAR | 1K words |
| 2026-09-29 | 0001493152-26-044802 | EDGAR | 1K words |
| 2026-08-25 | 0001493152-26-040080 | EDGAR | 1K words |
| 2026-08-24 | 0001493152-26-039898 | EDGAR | 1K words |
| 2026-08-13 | 0001493152-26-037794 | EDGAR | 3K words |
| 2026-08-06 | 0001493152-26-036268 | EDGAR | 2K words |
| 2026-07-15 | 0001493152-26-033360 | EDGAR | 1K words |
| 2026-04-03 | 0001493152-26-015139 | EDGAR | 1K words |
| 2026-03-30 | 0001493152-26-013622 | EDGAR | 3K words |
215 total filings indexed. 184 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001716947 |
| Ticker | ENSC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | La Jolla, California |
| Website | https://www.ensysce.com |
| Listed | 2021-07-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ENSC (~200 tokens, structured JSON with cryptographic provenance)